Loktionov A, Bingham S A, Vorster H, Jerling J C, Runswick S A, Cummings J H
Medical Research Council, Dunn Clinical Nutrition Centre, Cambridge, UK.
Br J Nutr. 1998 Feb;79(2):133-9. doi: 10.1079/bjn19980024.
Apolipoprotein E (ApoE) genotype was determined in sixty-five subjects who had taken part in a 4-week randomized crossover trial to compare the effect of six mugs of black tea per day v. placebo on blood lipids and blood coagulation factors. Four ApoE genotype variants (seven E2/E3, forty-five E3/E3, twelve E3/E4 and one E4/E4) were found. ApoE allele frequency was within the range typical for Caucasian populations (ApoE-E2 5.4%; ApoE-E3 83.8%; ApoE-E4 10.8%). Individuals bearing at least one E4 allele had substantially higher levels of serum total cholesterol, LDL cholesterol and triacylglycerols. Mean plasminogen activator inhibitor (PAI-1) activity was higher in ApoE-E4 allele-bearing individuals (E3/E4 + E4/E4, 11.89 (SE 1.27) U/ml; E3/E3, 9.19 (SE 0.80) U/ml; E2/E3, 7.21 (SE 1.04) U/ml, P values of E4-group v. E3 and E2 being respectively 0.093 and 0.030). These unexpected findings imply that elevated PAI-1 activity may be a hitherto unrecognized additional factor involved in the increased cardiovascular disease risk associated with apoE-E4 allele. The interactions between tea drinking and genotype were also examined. In the E3/E3 homozygotes, HDL-cholesterol was significantly reduced in the tea period (mean placebo 1.54 mmol/l v. mean tea 1.50 mmol/l, P = 0.027). In the E2/E3 group, triacylglycerol concentration was significantly reduced (mean placebo 1.18 mmol/l v. mean tea 1.09 mmol/l, P = 0.039). Tea also caused a significant decrease of PAI-1 activity in the subjects with E2/E3 genotype (mean placebo 7.21 U/ml v. mean tea 5.88 U/ml, P = 0.007). In the other two genotype groups, there was no significant effect of tea. The results indicate that tea drinking has a beneficial effect on some cardiovascular disease risk-associated factors, especially in E2 allele-bearing individuals. Dietary intervention may be particularly effective in population groups with certain genetic characteristics.
对65名参与了一项为期4周随机交叉试验的受试者进行了载脂蛋白E（ApoE）基因型测定，该试验旨在比较每天饮用6杯红茶与饮用安慰剂对血脂和血液凝固因子的影响。发现了4种ApoE基因型变体（7名E2/E3、45名E3/E3、12名E3/E4和1名E4/E4）。ApoE等位基因频率在高加索人群的典型范围内（ApoE-E2 5.4%；ApoE-E3 83.8%；ApoE-E4 10.8%）。携带至少一个E4等位基因的个体血清总胆固醇、低密度脂蛋白胆固醇和三酰甘油水平显著更高。在携带ApoE-E4等位基因的个体中，纤溶酶原激活物抑制剂（PAI-1）的平均活性更高（E3/E4 + E4/E4，11.89（标准误1.27）U/ml；E3/E3，9.19（标准误0.80）U/ml；E2/E3，7.21（标准误1.04）U/ml，E4组与E3组和E2组相比的P值分别为0.093和0.030）。这些意外发现表明，PAI-1活性升高可能是与apoE-E4等位基因相关的心血管疾病风险增加中一个迄今未被认识到的额外因素。还研究了饮茶与基因型之间的相互作用。在E3/E3纯合子中，饮茶期间高密度脂蛋白胆固醇显著降低（安慰剂均值1.54 mmol/l对茶均值1.50 mmol/l，P = 0.027）。在E2/E3组中，三酰甘油浓度显著降低（安慰剂均值1.18 mmol/l对茶均值1.09 mmol/l，P = 0.039）。茶还使E2/E3基因型受试者的PAI-1活性显著降低（安慰剂均值7.21 U/ml对茶均值5.88 U/ml，P = 0.007）。在其他两个基因型组中，茶没有显著影响。结果表明，饮茶对一些与心血管疾病风险相关的因素有有益作用，尤其是在携带E2等位基因的个体中。饮食干预在具有某些遗传特征的人群中可能特别有效。
